Effect of SLC30A8 rs13266634 Genetic Polymorphism on Zinc Supplementation and Glycemic Control in Egyptian Patients With Type 2 Diabetes Mellitus
NCT ID: NCT03112382
Last Updated: 2017-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
80 participants
INTERVENTIONAL
2015-11-30
2017-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Zinc in Patients With Type 2 Diabetes
NCT06751823
Nutrigenomics of Zinc Supplementation in Insulin Secretion and Diabetes
NCT00981448
Effect of Zinc on Glucose Homeostasis
NCT05835037
Effects of Zinc Supplementation on Patients With Elevated Glycemic Status
NCT06807996
Zinc Supplementation Improves Cardiovascular Morbidity in Patients With Diabetes Mellitus
NCT05000762
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SCREENING
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
zinc supplement plus vitamin A and E
patients will be receiving zinc supplement plus vitamin A and E for 3 months.
zinc supplement plus vitamin A and E
vitamin A and E
patients will be receiving equivalent dose of vitamin A and E only for 3 months
vitamin A and E
no vitamins
patients will be observed for 3 months
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
zinc supplement plus vitamin A and E
vitamin A and E
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 20 and 64 years.
* BMI \< 40 kg/m2.
* On fixed oral hypoglycemic dosage for at least 3 months.
* Normal serum creatinine (0.5 to 1.3 mg/dL) with no clinical evidence suggestive kidney disease.
* Normal liver function tests (ALT 7 to 55 U/L, and albumin ˃ 3.5 g/dL).
Exclusion Criteria
* Those who were taking multivitamin containing zinc or magnesium or any sort of mineral supplements in the previous three months or hormone replacement therapy (estrogen, progesterone) or chelating therapy such as penicillamine, or anticonvulsant (phenytoin, valproate).
* Those with a history of recent surgery or with concurrent acute illness including infectious disease, trauma, inflammatory bowel disease, malignancy, and active immunological diseases, using corticosteroids.
* Pregnant or intend to be pregnant for t least 3 months or lactating women.
* Those who were receiving insulin preparations as a part of diabetes management.
20 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eman Said
Assisstant lecturer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
theoutpatient clinics, department of internal medicine, Cairo University teaching hospitals,
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CL (1461)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.